A Little Bit of Cash for ArQule

Development-stage drugmaker ArQule (Nasdaq: ARQL  ) announced yesterday that it had received a milestone payment for discovery-stage drug work that it performed for partner Wyeth (NYSE: WYE  ) .

Like other chemistry or drug discovery specialists, such as Pharmacopeia (Nasdaq: PCOP  ) and Array BioPharma (Nasdaq: ARRY  ) , ArQule has partnerships with a number of big pharmaceutical companies that it helps identify suitable drug candidates to bring into human clinical trial testing.

ArQule's deal with Wyeth was part of its former chemistry operations, which ArQule terminated in the middle of 2006 so it could focus on its own oncology drug development programs. The Wyeth deal was part of legacy operations, and the milestone payment that Wyeth made yesterday was related to an Alzheimer's disease drug candidate from this deal.

ArQule stands to gain royalties and milestone payments on this drug candidate, now in phase 1 clinical study, if the drug makes it to market. When you're a development-stage pharma like ArQule, any cash from milestone payments helps. But ArQule didn't disclose the size of the payment from Wyeth, so we can surmise that it was not a huge amount of money.

ArQule has other deals with drugmakers such as Roche. Its two lead oncology compounds are in phase 2 testing with several other cancer-fighting compounds in earlier stages of development. The Wyeth deal may not mean much to ArQule any more, but it reminds us that ArQule's roots lie with its chemistry services operations, which could provide much-needed cash down the road.

More Foolishness on developmental-stage drugmakers:

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 608196, ~/Articles/ArticleHandler.aspx, 10/21/2016 12:52:42 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,113.74 -48.61 -0.27%
S&P 500 2,138.01 -3.33 -0.16%
NASD 5,249.39 7.55 0.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 12:31 PM
ARQL $1.49 Up +0.07 +4.93%
ArQule CAPS Rating: ***
ARRY $6.56 Down -0.02 -0.30%
Array BioPharma CAPS Rating: **
PCOP $1.74 Down +0.00 +0.00%
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***